Decrease in the rate of secondary amyloidosis in Turkish children with FMF: are we doing better?

Victoria Akse-Onal1, Erdal Sağ, Seza Ozen

  • 1Department of Pediatrics, Hacettepe University, Ankara 06100, Turkey.

Insights

Secondary amyloidosis, a complication of Familial Mediterranean Fever (FMF), significantly decreased in Turkey. Improved FMF treatment and potentially environmental factors contributed to this decline.

Area of Science:

  • Rheumatology
  • Nephrology
  • Genetics

Background:

  • Familial Mediterranean Fever (FMF) is a prevalent autoinflammatory disorder.
  • Secondary amyloidosis is a severe complication of FMF, influenced by genetic and environmental factors.

Purpose of the Study:

  • To assess the change in secondary amyloidosis rates in Turkey over time.
  • To identify potential factors contributing to observed changes in amyloidosis incidence.

Main Methods:

  • Comparative analysis of clinical features of FMF patients with secondary amyloidosis.
  • Data collected from two distinct periods: 1978-1990 and 2000-2009.
  • Utilized a modified scoring system for assessing disease severity in pediatric patients.

Main Results:

  • A significant reduction in secondary amyloidosis was observed, decreasing from 12.1% (1978-1990) to 2% (2000-2009) of renal biopsies.
  • No significant differences in patient demographics (gender, age, onset, duration, severity) were found between the two groups.
  • The incidence of secondary amyloidosis among FMF patients in Turkey has markedly decreased.

Conclusions:

  • Improved FMF management, including increased awareness and treatment, is the primary driver for reduced secondary amyloidosis.
  • Potential positive impact of an improved infectious environment on this monogenic autoinflammatory disease warrants further investigation.